Ooni Koda
  1. Home
  2. /
  3. Newsfeed
  4. /
  5. Survey: Only 17% accessibility rate for Romanians to...

Survey: Only 17% accessibility rate for Romanians to new medicines approved at European level in 2019-2022

July 18, 2024

  Romanians have access to only 17% of the medicines approved at European level in the period 2019-2022, in 2023, no new medicines were unconditionally subsidised in our country, and in 2024 only 28 new medicines were included in the list of those subsidised, according to data from the study of the European Federation of Pharmaceutical Industries and Associations (EFPIA) on the Indicator of Access to Innovative Medicines Patients W.A.I.T. (Waiting to Access Innovative Therapies) for 2023.The Romanian Association of International Manufacturers of Medicines (ARPIM) made public on Thursday a series of data from three reports published in June 2024 by EFPIA, data collected from 36 countries (27 from the EU and 9 from outside the EU) that provide information on the 167 innovative medicines with centralized marketing authorization in the period 2019-2022.Dr. Ioana Bianchi, Director of Foreign Affairs at ARPIM, said that, according to the study data, in Romania, the availability rate of oncological drugs was 19% (out of the 48 that received European approval between 2019 and 2022, only 9 were available in Romania on January 5, 2024) as well as in the case of "orphan" drugs (drugs dedicated to the treatment of rare diseases) which was also 19%.Out of 167 innovative medicines that received approval from the European Medicines Agency (EMA) between 2019 and 2022, only 29 medicines were available in Romania on 5 January 2024. No medicine approved at European level in 2022 was subsidised in Romania on January 5, 2024.The drop is dramatic compared to last year's similar study, which showed an availability rate of 30% (51 drugs), the study data also highlights.As for the access time, i.e. the time from approval by the European Medicines Agency (EMA) to availability in Romania, it is 778 days, while German patients, for instance, have access to state-of-the-art medicines in just 126 days, according to the data presented by Dr. Bianchi.In our country, the main reasons why pharmaceutical companies have to wait to submit their evaluation files are: the evaluation criteria, the technical and human infrastructure necessary for diagnosing diseases, so the average time for submitting files is 86 days, but the average time for a reimbursement decision is 563 days, the data of the said study reads.  

Read in full - click here
100 specialists to work non-stop at new subway tunnel to Bucharest’s Otopeni Airport

Around 100 specialists will work around the clock, in three shifts, at the 1 Mai – Băneasa subway tunnel section, part of the line extending to Otopeni Airport, according to secretary-general of the Ministry of Transport, Mariana Ioniță. The first TBM machine, which will begin drilling the tunnel, is set to arrive on Monday, March […]

Report: Scale of child trafficking cases in Romania underreported, sexual exploitation most common

A new report from the Romanian branch of NGO Justice and Care shows that the scale of the child trafficking phenomenon is underestimated by the authorities and that sexual exploitation, particularly of girls, remains the primary form of trafficking.  The study, based on field research and interviews with specialists from three counties, namely Dolj, Bacău, […]

Romania opens honorary consulate in Pakistan’s Peshawar region

The Romanian Embassy in Pakistan has opened an honorary consulate in Peshawar, covering the Khyber Pakhtunkhwa region. The country is a major source of workers, essential in filling Romania’s labor shortage. Dan Stoenescu, Romania's Ambassador to Pakistan, inaugurated the Honorary Consulate in a special ceremony attended by government officials, business leaders, and members of the […]

EVERGENT Investments reports a net result of RON 263.66 mln in 2024, up 29% compared to 2023, and a total EVER share return of 22.94%, significantly exceeding BET-TR’s 16.15%

EVERGENT Investments, an investment company listed under the ticker EVER, reports a net result of RON 263.66 million for the year 2024, representing a 29% year-over-year increase, surpassing the budgeted level by 175%. The net result is the company’s main performance indicator and consists of net profit and net gains from the sale of financial […]

Romanian courier company Sameday acquires 24.9% stake held by eMAG in Zitec

Sameday, one of the key players in the courier industry, acquired the 24.9% stake held by eMAG in local IT firm Zitec, entering the company's shareholding structure. The transaction is subject to regulatory approval. "Changes in the logistics and courier sectors require rapid adaptations and technological solutions to address the challenges. The growing demand for […]

Tomcat from Romania crowned Europe’s most beautiful in 2025

Nexus, an 8-month silver British shorthair with blue eyes, was crowned Europe’s most beautiful tomcat at the European Feline Championship 2025, an event held in Warsaw, Poland. The tomcat, by his full name Nexus of Winter Foxes, is owned by Oana Pintilii and Alexandru Paraschiv, breeders who have dedicated seven years to this passion.  Nexus’s […]